Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: William Partmann who wrote (1199)	1/14/2000 11:49:00 AM
From: William Partmann	Read Replies (1) \| Respond to of 1686

RESEARCH ALERT - Several brokerages raise Biogen NEW YORK, Jan 14 (Reuters) - Several brokerages on Friday raised their price targets and earnings estimates for Biogen Inc. (NasdaqNM:BGEN - news) after the multiple sclerosis drug maker reported strong-than-expected profits. -- Late Thursday, Biogen reported fourth-quarter earnings of $69.3 million, or 44 cents per diluted share, topping analysts expectations by 2 cents. -- Firm posted higher total sales of $225.3 million for the quarter vs. $168.3 million a year earlier, and said it would spend $300 million on research and development in 2000. -- Company said number of Avonex patients surged nearly 50 percent from year earlier to 83,000, and yearly sales jumped 55 percent to $621 million from $395 million. -- Company forecast number of Avonex MS drug patients rising to over 100,000 in 2000 from 83,000 currently. -- US Bancorp Piper Jaffray analyst Peter Ginsberg on Friday said he upped Biogen 2000 eps view to $1.83 from $1.76. -- Piper said upped 2001 eps view to $2.10 from $2.05. -- Piper said raised price target to $84 from $82. -- said strong Avonex sales in line with Piper's forecast. -- said quarterly increase in Avonex patients signals U.S. sales growth far from abating. -- said reiterated neutral rating. -- said management plans 2000 goal of in-licensing 2 drugs in clinical development. -- Warburg Dillon Read analyst Rachel Leheny on Friday raised Biogen 2000 eps view to $1.80 from $1.60, upped 2001 to $1.98 from $1.80. -- Upped estimates based on company guidance for sales and costs for year 2000. -- said quarterly Avonex sales of $180 million beat Warburg's $168 million estimate. -- Goldman Sachs on Friday said analyst May-Kin Ho raised 2000 EPS estimate for Biogen to $1.88 from $1.72, and introduced a 2001 EPS estimate of $2.32. -- rated the stock a Market Outperformer. -- Lehman Brothers Inc analyst Tony Butler on Friday raised his 2000 eps view on Biogen to $1.85 from $1.73. -- said based on company's guidance for Avonex patient growth and research and development costs, upped estimates. -- said raised price target to $120 from $95. -- said quarterly Avonex sales modestly above Lehman's estimates. -- shares rose 3-7/16 to 80-3/4 in late morning Nasdaq trade. -- PaineWebber analyst Elise Wang said on Friday she raised estimates for 2000 to $1.81 from $1.75, and 2001 to $2.11 from $2.02. -- said ``we believe that increased use in earlier-stage (Avonex) patients is continuing to drive robust market expansion.' -- said ``With this strong growth, we expect Biogen will achieve its goal of 100,000 patients treated with Avonex by Q3 2000.' -- said she was increasing her Avonex sales projection to $822 million from $812 million with aggregate revenues reaching nearly $1 billion for 2000. -- said ``Our 2001 EPS estimate is also increased to $2.11 based on Avonex sales of $993 million from $2.02 per share on Avonex sales of $945 million.' -- said reiterating Buy rating. --------------------------------------------------------------------------------